Craft

BenevolentAI

Stock Price

€0.8

2024-02-16

Market Capitalization

€91.6 M

2024-02-16

Revenue

€10.6 M

FY, 2022

BenevolentAI Summary

Company Summary

Overview
BenevolentAI is a clinical-stage AI-enabled drug discovery company. It offers an AI platform, scientific expertise, and wet-lab facilities. The Benevolent Platform powers a growing in-house pipeline of 20+ disease programs and maintains collaborations with other drug discovery companies and research and charitable institutions.
Type
Public
Status
Active
Founded
2013
HQ
London, GB | view all locations
Website
https://www.benevolent.com/
Cybersecurity rating
Sectors

Key People

  • Olivier Brandicourt

    Olivier Brandicourt, Non-Executive Director

    • Susan Liautaud

      Susan Liautaud, Non-Executive Director

      • Ivan Griffin

        Ivan Griffin, COO and Co-Founder

      • Nigel Shadbolt

        Nigel Shadbolt, Non-Executive Director

        Operating MetricsView all

        Trademarks Pending

        2

        May, 2020

        LocationsView all

        3 locations detected

        • London, England HQ

          United Kingdom

          4-8 Maple St, Bloomsbury

        • New York, NY

          United States

          1 Dock 72 Way, 7th Floor

        • Babraham, England

          United Kingdom

          Babraham Hall House

        BenevolentAI Financials

        Summary Financials

        Revenue (FY, 2022)
        €10.6M
        Gross profit (FY, 2022)
        €10.7M
        Net income (FY, 2022)
        (€163.9M)
        Cash (FY, 2022)
        €88.4M
        EBIT (FY, 2022)
        (€197.0M)
        Enterprise value
        $3.2M

        Footer menu